HRP20050534A2 - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
HRP20050534A2
HRP20050534A2 HR20050534A HRP20050534A HRP20050534A2 HR P20050534 A2 HRP20050534 A2 HR P20050534A2 HR 20050534 A HR20050534 A HR 20050534A HR P20050534 A HRP20050534 A HR P20050534A HR P20050534 A2 HRP20050534 A2 HR P20050534A2
Authority
HR
Croatia
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
HR20050534A
Other languages
English (en)
Croatian (hr)
Inventor
Canton Thierry
Pradier Laurent
Benavides J�sus
Heuer Hubert
Schaefer Hans-Ludwig
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20050534A2 publication Critical patent/HRP20050534A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HR20050534A 2002-12-12 2005-06-10 Prevention and treatment of alzheimer's disease HRP20050534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
HRP20050534A2 true HRP20050534A2 (en) 2006-11-30

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050534A HRP20050534A2 (en) 2002-12-12 2005-06-10 Prevention and treatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (xx)
JP (1) JP2006514063A (xx)
KR (1) KR20050084250A (xx)
CN (1) CN1726016A (xx)
AR (1) AR042354A1 (xx)
AU (1) AU2003296802A1 (xx)
BR (1) BR0317280A (xx)
CA (1) CA2507945A1 (xx)
CO (1) CO5700712A2 (xx)
FR (1) FR2848452B1 (xx)
HR (1) HRP20050534A2 (xx)
MA (1) MA27500A1 (xx)
MX (1) MXPA05005556A (xx)
NO (1) NO20053341L (xx)
NZ (1) NZ540496A (xx)
PE (1) PE20040770A1 (xx)
PL (1) PL377110A1 (xx)
RS (1) RS20050420A (xx)
RU (1) RU2005121909A (xx)
TW (1) TW200503707A (xx)
WO (1) WO2004062652A1 (xx)
ZA (1) ZA200504656B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) * 2007-05-22 2019-07-10 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
NO20053341D0 (no) 2005-07-08
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
MXPA05005556A (es) 2005-07-26
RS20050420A (xx) 2007-04-10
TW200503707A (en) 2005-02-01
EP1572174A1 (fr) 2005-09-14
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
CN1726016A (zh) 2006-01-25
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease
DE60112055D1 (de) Inhibitoren von gamma-secretase
BR9914044A (pt) ésteres tetrahidropirido
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ECSP045429A (es) Combinacion de compuestos organicos
UY27972A1 (es) Derivados de hidantoína
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
PA8577901A1 (es) Formulacion farmaceutica
EP1764092A3 (en) Selecting compounds for treatment of Alzheimer's disease
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
EE05556B1 (et) 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
PT1115701E (pt) Ureias de arilsulfonanilida
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ZA200710415B (en) Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
MXPA04000793A (es) Novedoso metodo terapeutico.
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
NO20054744L (no) Behandling av Alzheimers sykdom
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
NO20076405L (no) Anvendelse av 24-nor-UDCA

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071207

Year of fee payment: 5

OBST Application withdrawn